Liothyronine (LT3) prescribing in England: Are cost constraints inhibiting guideline implementation?

Heald Ah(Manchester Academic Health Science Centre), Dayan CM, Mike Stedman, Peter Taylor(University Hospital of Wales), Dasha Depesina(Research Institute of Ukrainian Studies), Nadia Chaudhury(University Hospitals Coventry and Warwickshire NHS Trust), OE Okosieme(Cwm Taf University Health Board), Lakdasa Premawardhana(Ysbyty Ystrad Fawr)
Clinical Endocrinology
May 16, 2024
10.1111/cen.15061
Cited by 4

Related Papers

Global epidemiology of hyperthyroidism and hypothyroidism
|Nature Reviews Endocrinology|2018|1.5k
Incidence, prevalence, and co-occurrence of autoimmune disorders over time and by age, sex, and socioeconomic status: a population-based cohort study of 22 million individuals in the UK
|The Lancet|2023|838
Association of Thyroid Function Test Abnormalities and Thyroid Autoimmunity With Preterm Birth
|JAMA|2019|395
New insights into the pathogenesis and nonsurgical management of Graves orbitopathy
|Nature Reviews Endocrinology|2019|315
Falling Threshold for Treatment of Borderline Elevated Thyrotropin Levels—Balancing Benefits and Risks
|JAMA Internal Medicine|2013|299